Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity
Lee A. Dawson, Zoë A. Hughes, Kathryn R. Starr, James D. Storey, Letizia Bettelini, Fabrizio Bacchi, Roberto Arban, Alessandro Poffe, Sergio Melotto, James J. Hagan, Gary W. PriceVolume:
50
Year:
2006
Language:
english
DOI:
10.1016/j.neuropharm.2006.01.010
File:
PDF, 423 KB
english, 2006